|
Daniel's Biotech Briefing
Distilled Bio uses AI to process and generate content for you. Verify important details using the linked sources.
AI-generated briefing: Fortrea expands its clinical-trials platform, Anthropic and Notion emerge as IPO candidates, and biotech leaders rethink strategy amid regulatory uncertainty.
The top 10 stories from Wed Sep 2, 2026 07:09 AM to Thu Sep 3, 2026 07:09 AM
Generated September 3, 2026 at 7:09 AM
|
|
|
#1 Navigating the Regulatory Labyrinth: How Biotech Leaders Are Rethinking Strategy in an Uncertain Regulatory Era Published 2026-09-02 Biotech executives are adjusting pipeline sequencing, capital allocation, partnerships, and FDA engagement amid uncertainty from leadership changes, enforcement shifts, and evolving approval policies. Covered by: genengnews.com |
#2 Follow the money: How funding announcements can help identify jobs before they’re posted Published 2026-09-02 Biotech funding announcements, milestones, and company indicators may help professionals anticipate hiring activity and connect with employers before jobs are posted. Covered by: biospace.com |
#3 Typewriter Therapeutics Emerges from Stealth with $56 Million Series A Financing to pursue in vivo CAR T medicines Published 2026-09-02 Typewriter Therapeutics launched with $56 million in Series A financing to develop in vivo CAR T medicines using LNP-delivered RNA gene insertion technology. Covered by: prnewswire.com, endpoints.news |
#4 K2 Therapeutics: Spreading bets across range of Asia-sourced assets Published 2026-09-03 K2 Therapeutics, led by former Legend CEO Ying Huang, is seeking a $250 million Series A to develop a diversified portfolio of Asia-sourced assets. Covered by: biocentury.com |
#5 Fortrea boosts early-phase CRO platform with $45M acquisition of Worldwide division Published 2026-09-02 Fortrea agreed to acquire Worldwide Clinical Trials’ early-phase services division for $45 million, expanding its early-phase contract research organization capabilities. Covered by: fiercebiotech.com |
#6 STAT+: ARPA-H funds biotechs working on custom RNA therapies Published 2026-09-02 UniQure submitted applications to the FDA and UK MHRA seeking approval for AMT-130, an investigational Huntington’s disease treatment. Covered by: statnews.com |
#7 The IPO Window Is Closing. Here Are 8 Startups To Watch. Published 2026-09-02 Crunchbase identifies eight venture-backed companies, including Anthropic, Oura, and Notion, as potential IPO candidates within the next six months. Covered by: news.crunchbase.com |
#8 Pareto Securities Healthcare Conference: Mendus' cellular immunotherapy has been making progress in numerous cancers - being thoughtful about the setting and goal of treatment have been keys Published 2026-09-02 Mendus CEO Erik Manting discussed vididencel’s progress in AML, CML, and ovarian cancer, with additional CML data expected in the second half of the year. Covered by: biotechtv.com |
#9 NovaGo Therapeutics Closes USD 30 Million Series B Financing to Advance Proof-of-Concept Study in Acute Spinal Cord Injury Published 2026-09-02 NovaGo Therapeutics raised $30 million in Series B financing, led by Neurimmune and Pureos, to advance a proof-of-concept study for acute spinal cord injury. Covered by: prnewswire.com, prnewswire.com |
#10 Insilico Medicine Included in the HKEX Tech 100 Index, Drawing Attention to Opportunities in AI Value Chain Published 2026-09-03 Insilico Medicine announced its inclusion in the HKEX Tech 100 Index following methodology enhancements. Covered by: prnewswire.com |
